Napradiol (Diclofenac Sodium, Omeprazole)

Napradiol combines an NSAID with a proton‑pump inhibitor to manage pain‑related conditions and protect the gastrointestinal tract.

• Osteoarthritis: reduces joint pain and inflammation, improving mobility.
• Rheumatoid arthritis: alleviates chronic joint inflammation and pain.
• Musculoskeletal pain: provides relief for acute or chronic muscle and tendon discomfort.
• Gastro‑protective therapy for patients receiving NSAIDs: lowers the risk of ulceration and bleeding by suppressing gastric acid secretion.

• Diclofenac sodium inhibits cyclooxygenase (COX‑1 and COX‑2) enzymes, decreasing prostaglandin synthesis and thereby reducing inflammation and pain. Omeprazole irreversibly binds to the gastric H+/K+ ATPase pump, blocking the final step of acid secretion and providing sustained gastro‑protection.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Abdominal pain: discomfort in the stomach area.
• Diarrhea: loose stools.
• Rash: mild skin irritation.

Serious or Rare Side Effects

• Gastrointestinal ulceration or bleeding: severe stomach or intestinal lesions.
• Liver enzyme elevation: signs of hepatic stress.
• Severe skin reactions (e.g., Stevens‑Johnson syndrome): extensive rash or blistering.
• Renal impairment: reduced kidney function.
• Cardiovascular events: increased risk of heart attack or stroke.
• Anaphylaxis: rare, potentially life‑threatening allergic reaction.

Before initiating therapy, consider the following safety measures.

• Renal function assessment: evaluate kidney health, especially in the elderly.
• Hepatic monitoring: check liver enzymes periodically.
• Lowest effective NSAID dose: use the minimal dose needed for symptom control.
• History of ulcer disease: avoid in patients with active peptic ulcers.
• Concomitant anticoagulant use: monitor bleeding risk closely.
• Pregnancy and breastfeeding: safety not established; use only if clearly needed.
• Store at ambient temperature: keep in the original pack, protect from moisture.

Drug‑drug interactions may alter efficacy or increase toxicity.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): heightened bleeding risk.
• Other NSAIDs or aspirin: additive gastrointestinal toxicity.
• Lithium: increased serum lithium levels.
• Methotrexate: reduced clearance, potential toxicity.
• Cyclosporine: elevated cyclosporine concentrations.

Moderate Interactions (Monitor Closely)

• SSRIs (e.g., sertraline): modest increase in bleeding risk.
• ACE inhibitors (e.g., enalapril): possible reduction in renal function.
• Diuretics (e.g., furosemide): may affect kidney handling of NSAIDs.
• Corticosteroids (e.g., prednisone): additive ulcer risk.
• Antidiabetic agents (e.g., metformin): monitor blood glucose control.